Misonix, Inc. Announces the Grant of Patent by the United States Patent and
Medical Handpiece with Automatic Power Switching Means
FARMINGDALE, N.Y., June 12, 2013
FARMINGDALE, N.Y., June 12, 2013 /PRNewswire/ --Misonix, Inc. (NASDAQ: MSON),
a surgical device company that designs, manufactures and markets innovative
therapeutic ultrasonic products worldwide for spine surgery, cranial maxillo –
facial surgery, neurosurgery, wound debridement, cosmetic surgery,
laparoscopic surgery and other surgical applications, today announced today
that is has received a new U.S. patent on the Company's medical device
products. The patent describes a means to control the output of various
powered surgical devices such that power can be applied only at times where
the tool is translated forward in the operative site and not at other times.
By limiting power on to only the time required, tissue heating is reduced
thereby improving procedure outcome and enhancing safety along with surgeon
ergonomics. This action does not require the surgeon to activate switches or
other mechanical means so that the action is transparent to the user.
To date this year, six patents have been issued to Misonix, many of which
apply to the Company's ultrasonic platform in general and to its BoneScalpel™
Michael A. McManus, Jr., President and CEO of Misonix stated, "Misonix
continues to grow and protect its core technology through continued
intellectual property development and patent submissions. We believe our
unique application of Ultrasound technology is one of our great assets which
will continue to create growth opportunities and value going forward."
Misonix, Inc. designs, manufactures and markets therapeutic ultrasonic medical
devices. Misonix's therapeutic ultrasonic platform is the basis for several
innovative medical technologies. Addressing a combined market estimated to be
in excess of $3 billion annually; Misonix's proprietary ultrasonic medical
devices are used for wound debridement, cosmetic surgery, neurosurgery,
laparoscopic surgery, and other surgical and medical applications. Additional
information is available on the Company's Web site at www.misonix.com.
Private Securities Litigation Reform Act of 1995
With the exception of historical information contained in this press release,
content herein may contain "forward looking statements" that are made pursuant
to the Safe Harbor Provisions of the Private Securities Litigation Reform Act
of 1995. These statements are based on management's current expectations and
are subject to uncertainty and changes in circumstances. Investors are
cautioned that forward looking statements involve risks and uncertainties that
could cause actual results to differ materially from the statements made.
These factors include general economic conditions, delays and risks associated
with the performance of contracts, risks associated with international sales
and currency fluctuations, uncertainties as a result of research and
development, acceptable results from clinical studies, including publication
of results and patient/procedure data with varying levels of statistical
relevancy, risks involved in introducing and marketing new products, potential
acquisitions, consumer and industry acceptance, litigation and/or court
proceedings, including the timing and monetary requirements of such
activities, the timing of finding strategic partners and implementing such
relationships, regulatory risks including approval of pending and/or
contemplated 510(k) filings, the ability to achieve and maintain profitability
in the Company's business lines, and other factors discussed in the Company's
Annual Report on Form 10 K, subsequent Quarterly Reports on Form 10 Q and
Current Reports on Form 8 K. The Company disclaims any obligation to update
its forward looking relationships.
Misonix Contact: Investor Relations Contact:
Richard Zaremba Joe Diaz, Lytham Partners
SOURCE Misonix, Inc.
Press spacebar to pause and continue. Press esc to stop.